Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | LMNA | P02545 | 6/20 | 0.52 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301695 | 0.84 | GAA (0.76) | GAAHTTNR3C1MAPTLMNA | |
| SCHEMBL3279971 | 0.82 | MAPT (0.61) | GAAHTTNR3C1MAPTLMNA | |
| SCHEMBL6553004 | 0.82 | PTPRB (0.54) | GAAHTTMAPTCACNA1HTP53 | |
| SCHEMBL3376969 | 0.81 | LMNA (0.60) | GAAHTTNR3C1MAPTLMNA | |
| SCHEMBL3278531 | 0.81 | HTT (0.57) | GAAHTTMAPTLMNACACNA1H | |
| SCHEMBL1965535 | 0.78 | MAPT (0.57) | GAAHTTMAPTLMNACACNA1H | |
| SCHEMBL6553016 | 0.77 | TGFBR1 (0.58) | — | |
| SCHEMBL3377228 | 0.77 | MAPT (0.74) | GAAHTTMAPTLMNAALDH1A1 | |
| SCHEMBL1965537 | 0.76 | MAPT (0.49) | GAAHTTNR3C1MAPTLMNA | |
| SCHEMBL302890 | 0.76 | HTT (0.51) | GAAHTTMAPTLMNACACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334637-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-8372840-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2013-02-12 | — | — | US | disclosed |
| EP-2334637-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-06-22 | — | — | EP | disclosed |
| US-20100087438-A1 | New Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| WO-2010023446-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087438-A1 | New Potassium Channel Blockers | KCNJ2, KCNB1, KCNJ11 | GAA 3871/4885HTT 3143/4885NR3C1 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.